• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Designing HIV-1 vaccines to reflect viral diversity and the global context of HIV/AIDS

Designing HIV-1 vaccines to reflect viral diversity and the global context of HIV/AIDS

by Adam | Oct 22, 2016

AIDScience 1(2) June 22, 2001.
Rapid Determination of HLA B*07- ligands from the West Nile Virus genome

Rapid Determination of HLA B*07- ligands from the West Nile Virus genome

by Adam | Oct 22, 2016

Emerging Infectious Diseases, Vol. 7, No. 4, July–August 2001: 706-713.
From genome to vaccine: In silico predictions, ex vivo verification

From genome to vaccine: In silico predictions, ex vivo verification

by Adam | Oct 22, 2016

Vaccine 2001 Aug 14; 19(31):4385-95.
Use of T cell epitopes for vaccine development

Use of T cell epitopes for vaccine development

by Adam | Oct 22, 2016

Current Drug Targets – Infectious Disorders, 2001, 1, 283-293.
Immuno-informatics: Mining the genome for Vaccine Components

Immuno-informatics: Mining the genome for Vaccine Components

by Adam | Oct 22, 2016

Immunology and Cell Biology. Immunology and Cell Biology (2002) 80, 255–269.
« Older Entries

Recent Posts

  • The Platinum Standard Vaccine
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar
  • Is “Artificial” Intelligence an Option for your ADA ?
  • Tregs as Medicine: Tolerance and InTolerance Seminar

Recent Comments

No comments to show.

Join our newsletter

 Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CSO, Dr. Annie De Groot. 

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline